~ Data to Form the Basis of ARIAD’s Regulatory Filings for Marketing
Approval of Ponatinib
~ Company to Host Investor Meeting and Webcast with Dr. Jorge Cortes
on Monday, June 4 at 12pm (CT)
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 16, 2012--
ARIAD
Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated
clinical data from the pivotal PACE trial of its investigational,
pan-BCR-ABL inhibitor, ponatinib,
will be presented at the Annual Meeting of the American Society of
Clinical Oncology (ASCO) being held in Chicago, June 1-5, 2012.
The updated findings from the PACE trial will be featured in an oral
presentation on Monday, June 4, 2012 and will also be highlighted in a
company-sponsored investor meeting to be webcast live from Chicago. This
trial is being conducted in patients with chronic myeloid leukemia (CML)
and Philadelphia-chromosome positive acute lymphoblasatic leukemia (Ph +
ALL) who are resistant or intolerant to either nilotinib or dasatinib,
two currently available CML therapies, or those who have the T315I
mutation of BCR-ABL for which no current treatments are known to be
effective. The ASCO presentation will include at least six months of
available response data from all patients enrolled in the trial and will
form the basis of ARIAD’s regulatory filings for marketing approval of
ponatinib in the U.S., Europe and other geographies.
The schedule and details for the oral presentation and investor meeting
are below:
|
Oral Presentation of Updated Response Data from Pivotal Phase
II PACE Trial
|
|
|
|
|
|
|
|
Title:
|
|
|
|
PACE: A Pivotal Phase II Trial of Ponatinib in Patients with CML and
|
|
|
|
|
|
Ph+ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the
|
|
|
|
|
|
T315I Mutation
|
|
Oral Session:
|
|
|
|
Leukemia, Myelodysplasia, and Transplantation
|
|
Date & Time:
|
|
|
|
Monday, June 4, 2012, 9:00 a.m. (CT)
|
|
Abstract No:
|
|
|
|
6503
|
|
Presenter:
|
|
|
|
Jorge E. Cortes, M.D. (The University of Texas MD Anderson Cancer
Center)
|
|
Location:
|
|
|
|
E354a
|
|
|
|
|
|
|
Investor and Analyst Briefing and Webcast
A lunch meeting to review the updated clinical data from the pivotal
PACE trial with research analysts and institutional investors will
feature Jorge Cortes, M.D., Distinguished Professor for Leukemia
Research, Deputy Chairman and Section Chief of the AML and CML programs
at the University of Texas MD Anderson Cancer Center, and members from
ARIAD management. Dr. Cortes has been an investigator in the Phase 1 and
Phase 2 trials of ponatinib. This meeting will be webcast live along
with slides and can be accessed by visiting the investor relations
section of the Company’s website at http://investor.ariad.com
or dialing: 888-396-2298 (domestic) or 617-847-8708 (international) and
providing the passcode 10684197.
|
Date:
|
|
|
|
|
|
Monday, June 4, 2012
|
|
|
|
|
|
|
|
|
|
Time:
|
|
|
|
|
|
12:00 p.m. to 1:00 p.m. (CT)
|
|
|
|
|
|
|
|
|
|
Location:
|
|
|
|
|
|
Chicago Hilton, Buckingham Room on lobby level
|
|
|
|
|
|
|
|
|
To attend the meeting, please RSVP to Investor.lunch@ariad.com
by Wednesday, May 30, 2012.
A replay of the investor event will be available on the ARIAD website
approximately three hours after the presentation and will be archived on
the site for four weeks. To ensure a timely connection to the live
webcast, participants should log onto the webcast at least 15 minutes
prior to the scheduled start time.
About ARIAD
ARIAD Pharmaceuticals, Inc. is an emerging global oncology company
focused on the discovery, development and commercialization of medicines
to transform the lives of cancer patients. ARIAD’s approach to
structure-based drug design has led to three internally discovered,
molecularly targeted product candidates for drug-resistant or
difficult-to-treat cancers, including certain forms of chronic myeloid
leukemia, soft tissue and bone sarcomas and non-small cell lung cancer.
For additional information, visit http://www.ariad.com
or follow ARIAD on Twitter.
Source: ARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc.
For Investors
Maria E.
Cantor, 617-621-2208
Maria.cantor@ariad.com
or
For
Media
Lynn Granito, 212-253-8881
lgranito@berrypr.com
